Cytosin-Arabinosid
High-grade B-cell Lymphoma
City of Hope Medical CenterPhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 73/ 100
Competitive context
32 Active assets in the High-grade B-cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE OHSU Knight Cancer Institute | Phase 3 | BB |
DEXAMETHASONE City of Hope Medical Center | Phase 3 | BB |
Cyclophosphamide National Cancer Institute (NCI) | Phase 3 | BB |
Inno-206 University of Washington | Phase 2 | B |
Eloxatin National Cancer Institute (NCI) | Phase 2 | B |
View all 41 →
Same molecule, other indications
Cytosin-Arabinosid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →